SAN CARLOS, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Qinotto, Inc., a central nervous system (CNS) focused biopharmaceutical company that is discovering novel vehicles to deliver large molecule therapeutics to the brain, announced today that it has entered a research collaboration and license agreement with Eli Lilly and Company (Lilly) to discover next-generation antibody-based vehicles for brain transport. Under this collaboration agreement, Qinotto will partner with Lilly Catalyze360-ExploR&D (https:// ...